For Immediate Release - sunshinebiopharma.com

For Immediate Release June 19, 2017 SUNSHINE BIOPHARMA FILES AN APPLICATION WITH HEALTH CANADA FOR A DRUG ESTABLISHMENT LICENSE Montreal, QC (Marketwired June 19, 2017) Sunshine Biopharma Inc. (OTC Markets: SBFM), a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications, is pleased to announce that it has filed an application for a Drug Establishment License ( DEL ) with Health Canada, the Canadian equivalent of the FDA in the United States. Obtaining a DEL is the first step in the certification process of a company to be able to handle drugs, including manufacturing, storage, tracking and distribution. Following the procurement of a DEL, the Company will apply for Drug Identification Numbers ( DIN s ) for its pharmaceutical products which are currently comprised of the following: Anastrozole (brand name Arimidex by AstraZenica) for treatment of Breast Cancer Letrozole (brand name Femara by Novartis) for treatment of Breast Cancer Bicalutamide (brand name Casodex by AstraZenica) for treatment of Prostate Cancer Finasteride (brand name Propecia by Merck)

For Immediate Release June 19, 2017 SUNSHINE BIOPHARMA FILES AN APPLICATION WITH HEALTH CANADA FOR A DRUG ESTABLISHMENT LICENSE Montreal, QC – (Marketwired – June 19, 2017) – Sunshine Biopharma Inc. …

Loading..

Information

Related search queries